Aug 21 2012 - ASCIA Position Paper and Action Plan for Hereditary Angioedema (HAE)
Hereditary Angioedema (HAE) is a very rare genetic disorder that currently affects around 100 Australians. People living with HAE suffer frequent acute, unpredictable and painful attacks of swelling (angioedema) anywhere in the body, which can be life threatening if they involve the airway or gut, and require urgent treatment in an emergency department.
The Australasian Society of Clinical Immunology and Allergy (ASCIA) has recently released a Position Paper and Action Plan for Hereditary Angioedema (HAE) and these are available on the ASCIA website: www.allergy.org.au/health-professionals/papers/hereditary-angioedema
The ASCIA Action Plan for HAE is based on the revised treatment algorithm (page 35 of the Position Paper) which incorporates the following TGA approved treatment options:
- Icatibant (Firazyr® - Shire Australia).
- Human C1 esterase inhibitor (Berinert® – CSL Biotherapies).
- Human nanofiltered C1 esterase inhibitor (Cinryze® – ViroPharma).
Whilst other treatments for HAE (attenuated androgens and antifibrolytics) are mentioned in the ASCIA Position Paper for HAE, their use is limited by side effects/intolerance, a relative lack of efficacy and increased risk of atherogenesis and liver disorders. These treatments are therefore not included in the ASCIA HAE treatment algorithm nor the ASCIA Action Plan for HAE
Please note that as the products listed in these documents are all TGA approved for Australia. As they are not yet all approved for New Zealand, the documents are currently specific for treatment of HAE in Australia.
More information will be available at the ASCIA 2012 HAE breakfast session on Friday 7 September in Wellington New Zealand. If you haven't yet registered for this meeting go to www.ascia2012.com